Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2005 1
2006 1
2007 1
2008 3
2009 4
2010 8
2011 6
2012 8
2013 7
2014 4
2015 6
2016 8
2017 9
2018 6
2019 9
2020 19
2021 23
2022 18
2023 15
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Results by year

Filters applied: . Clear all
Page 1
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.
Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, Gavilá J, Sampayo-Cordero M, Aguirre E, Schmid P, Marmé F, Di Cosimo S, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez-de Dueñas E, Amillano K, Malfettone A, Cortés J; PARSIFAL Steering Committee and Trial Investigators. Llombart-Cussac A, et al. JAMA Oncol. 2021 Dec 1;7(12):1791-1799. doi: 10.1001/jamaoncol.2021.4301. JAMA Oncol. 2021. PMID: 34617955 Free PMC article. Clinical Trial.
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, Dent S, Martin M, Ring A, Cottu P, Lu J, Ciruelos E, Azim HA, Chatterjee S, Zhou K, Wu J, Menon-Singh L, Zamagni C. De Laurentiis M, et al. Among authors: cottu p. Breast Cancer Res Treat. 2021 Oct;189(3):689-699. doi: 10.1007/s10549-021-06334-0. Epub 2021 Aug 19. Breast Cancer Res Treat. 2021. PMID: 34414532 Free PMC article. Clinical Trial.
Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers.
El-Botty R, Morriset L, Montaudon E, Tariq Z, Schnitzler A, Bacci M, Lorito N, Sourd L, Huguet L, Dahmani A, Painsec P, Derrien H, Vacher S, Masliah-Planchon J, Raynal V, Baulande S, Larcher T, Vincent-Salomon A, Dutertre G, Cottu P, Gentric G, Mechta-Grigoriou F, Hutton S, Driouch K, Bièche I, Morandi A, Marangoni E. El-Botty R, et al. Among authors: cottu p. Nat Commun. 2023 Jul 14;14(1):4221. doi: 10.1038/s41467-023-40022-5. Nat Commun. 2023. PMID: 37452026 Free PMC article.
Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis.
Vaz-Luis I, Di Meglio A, Havas J, El-Mouhebb M, Lapidari P, Presti D, Soldato D, Pistilli B, Dumas A, Menvielle G, Charles C, Everhard S, Martin AL, Cottu PH, Lerebours F, Coutant C, Dauchy S, Delaloge S, Lin NU, Ganz PA, Partridge AH, André F, Michiels S. Vaz-Luis I, et al. Among authors: cottu ph. J Clin Oncol. 2022 Jul 1;40(19):2148-2162. doi: 10.1200/JCO.21.01958. Epub 2022 Mar 15. J Clin Oncol. 2022. PMID: 35290073 Free PMC article.
[Emergency in oncologic patient's pathway].
Da Costa I, Cottu P, Bouleuc C, Moreau P. Da Costa I, et al. Among authors: cottu p. Bull Cancer. 2022 Dec;109(12):1277-1286. doi: 10.1016/j.bulcan.2022.06.012. Epub 2022 Sep 8. Bull Cancer. 2022. PMID: 36088177 French.
[Targeting the cyclin-dependent kinases 4/6 in advanced breast cancers].
Coussy F, Deluche E, Pistilli B, Ladoire S, Ferrero JM, Cottu P. Coussy F, et al. Among authors: cottu p. Bull Cancer. 2021 Sep;108(9):843-854. doi: 10.1016/j.bulcan.2021.04.007. Epub 2021 Jun 19. Bull Cancer. 2021. PMID: 34154797 Free article. Review. French.
Sustainable return to work among breast cancer survivors.
Ruiz de Azua G, Kousignian I, Vaz-Luis I, Di Meglio A, Caumette E, Havas J, Martin E, Martin AL, Querel O, Vanlemmens L, Pistilli B, Coutant C, Cottu PH, Merimeche AD, Lerebours F, Tredan O, Jouannaud C, Levy C, Dumas A, Menvielle G. Ruiz de Azua G, et al. Among authors: cottu ph. Cancer Med. 2023 Sep;12(18):19091-19101. doi: 10.1002/cam4.6467. Epub 2023 Aug 21. Cancer Med. 2023. PMID: 37602836 Free PMC article.
[Impact of the COVID-19 epidemic on requests for initial care for breast cancer].
Héquet D, Rodrigues M, Tardivon A, Langer A, Dahan M, Rouzier R, Takanen S, Kirova Y, Bidard FC, Cottu P. Héquet D, et al. Among authors: cottu p. Bull Cancer. 2020 Jun;107(6):620-622. doi: 10.1016/j.bulcan.2020.04.004. Epub 2020 Apr 30. Bull Cancer. 2020. PMID: 32389352 Free PMC article. French. No abstract available.
[New options in adjuvant endocrine therapy in breast cancer].
Saltel-Fulero A, Donnadieu A, Leman-Detours S, Cottu P. Saltel-Fulero A, et al. Among authors: cottu p. Bull Cancer. 2016 Jan;103(1):104-12. doi: 10.1016/j.bulcan.2015.10.011. Epub 2015 Dec 7. Bull Cancer. 2016. PMID: 26675809 Review. French.
[18F]FDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab.
Seban RD, Arnaud E, Loirat D, Cabel L, Cottu P, Djerroudi L, Hescot S, Loap P, Bonneau C, Bidard FC, Huchet V, Jehanno N, Berenbaum A, Champion L, Buvat I. Seban RD, et al. Among authors: cottu p. Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):4024-4035. doi: 10.1007/s00259-023-06394-y. Epub 2023 Aug 22. Eur J Nucl Med Mol Imaging. 2023. PMID: 37606858
147 results